Multiple Sklerose | MS-Monitoring mit molekularen Biomarkern - wo stehen wir? | springermedizin.de
Analysis of cardiac monitoring and safety data in patients initiating fingolimod treatment in the home or in clinic | BMC Neurology | Full Text
Analysis of cardiac monitoring and safety data in patients initiating fingolimod treatment in the home or in clinic | BMC Neurology | Full Text
Celestra Health entwickelt digitalen Biomarker für Multiple Sklerose mithilfe künstlicher Intelligenz und der intelligenten Sensorsohlen von Moticon
PDF) Canadian Experience with Fingolimod: Adherence to Treatment and Monitoring
Neue Therapiemodalitäten
Starting RRMS Treatment | GILENYA® (fingolimod)
Gavin Giovannoni, aka Prof G on X: "Just received this letter from Novartis UK. This is what happens when drugs go generic, i.e. support services disappear. We are told the switch from
Brain Sciences | Free Full-Text | Digital Biomarkers in Multiple Sclerosis
GILENYA®
Important things to remember about Gilenya® (fingolimod) treatment for patients, parents and caregivers
Fingolimod - Anwendung, Wirkung, Nebenwirkungen | Gelbe Liste
NDA 22-527 GILENYA (fingolimod) 0.5mg capsules RISK EVALUATION AND MITIGATION STRATEGY (REMS)
PDF) Analysis of cardiac monitoring and safety data in patients initiating fingolimod treatment in the home or in clinic
MS Minute: Oral Therapies for MS - Practical Neurology
January 2013 Direct Healthcare Professional Communication, refined guidance on when first dose monitoring procedures should
Interdisziplinäres Risikomanagement in der Therapie der multiplen Sklerose
The management and outcomes of fingolimod first dose cardiac monitoring in UK patients with relapsing-remitting multiple sclerosis - ScienceDirect
Building a monitoring matrix for the management of multiple sclerosis - ScienceDirect
Multiple Sklerose: Besseres Monitoring, fundiertere Behandlungsentscheidungen
New Multiple Sclerosis App For At Home Treatment Monitoring
MS - NYSORA | NYSORA
